Regor Therapeutics
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
50 Soldiers Field Pl, Boston, Massachuse...Phone Number
(317) 277-1838Website
www.regor.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Regor Therapeutics
Started in 2018 and based in Boston, Massachusetts, Regor Therapeutics is a biopharmaceutical company that specializes in developing therapeutics in the areas of oncology, metabolic diseases and autoimmune diseases.Explore more
Regor Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Regor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Regor Therapeutics recently announced quarterly report
Click to see if Regor Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Regor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Regor Therapeutics is spiking on competitors!
Regor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Regor Therapeutics
Funding: Get notified immidiatlly once Regor Therapeutics has new funding data
Product Launch: Get notified when Regor Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Regor Therapeutics
Find 3 more new buyers
Compare Similar Companies to Regor Therapeutics
Compare insights from companies similar to Regor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Regor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Regor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Regor Therapeutics.
Regor Therapeutics financials insights
Gather financial insights about Regor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$90M
Regor Therapeutics Tech Stack
A closer look at the technologies used by Regor Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Funding
Funding
Regor Therapeutics News & Media
Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer Partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancerRegor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo Enrollment opening for its COMO-1 Phase 2b dose-finding study to read out Q4 2025 CAMBRIDGE, Mass., Jan. 11, 2025 /PRNewswire/ -- Regor Therapeutics Group ("Regor"), a privately-held clinical-stage global biopharmaceutical compRegor Enters into a Definitive Purchase Agreement for Genentech to Acquire Regor's Portfolio of next-generation CDK inhibitors for the Treatment of Breast Cancer
Genentech will acquire Regor's next-generation CDK inhibitors for an upfront payment of $850 million in cash. Regor is also eligible to receive additional cash payments contingent on achieving future development, regulatory and commercial milestones CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- Regor Pharmaceuticals (USA) ("Regor") has entered into a definitive purchase agreement whereby Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors from ReRegor to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 5, 2024 /PRNewswire/ -- Regor Therapeutics Group, a clinical-stage global biopharmaceutical company, today announced the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Thursday, June 12. Dr. Xiayang Qiu, Founder and CEO, will represent the Company in a session scheduled at 11:20 am (Eastern Time) on June 12. About Regor Therapeutics Group Regor Therapeutics Group ("Regor") is founded in 2018 by a team of scientists with a proven
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Regor Therapeutics
Sign Up For FreeTo access detailed company insights
Started in 2018 and based in Boston, Massachusetts, Regor Therapeutics is a biopharmaceutical company that specializes in developing therapeutics in the areas of oncology, metabolic diseases and autoimmune diseases.... Read More
